Stockscreener 앱 받기
8.52
0.12%
0.010
시간 외 거래:
8.52
Y Mabs Therapeutics Inc 주식(YMAB)의 최신 뉴스
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Truist Financial - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Rating Lowered by Brookline Capital Management - MarketBeat
DeFi Technologies Provides Monthly Corporate Update: Valour Reports US$947 Million (C$1.3 Billion) in AUM, and Monthly Net Inflows of US$14.4 Million (C$19.8 Million) in July 2025, Among Other Key Developments - The Globe and Mail
Y-mAbs Therapeutics (NASDAQ:YMAB) Given Hold Rating at Jones Trading - MarketBeat
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Neutral" Rating from HC Wainwright - MarketBeat
Y-mAbs Therapeutics 2025 Q2 Earnings Narrowed Losses and Pending Acquisition - AInvest
Y-mAbs Therapeutics Reports Q2 Earnings and Acquisition - TipRanks
SERB Pharmaceuticals Acquires Y-MAbs As Revenue Slides - Finimize
Y-mAbs (YMAB) Q2 Revenue Falls 14% - AOL.com
Y-mAbs Therapeutics Q2 Earnings: Revenue Meets Expectations, EPS Below Consensus - AInvest
Y-mAbs Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Y mAbs Therapeutics earnings beat by $0.19, revenue topped estimates - Investing.com Canada
Y-mabs sold to Serb Pharmaceuticals for USD 412m - medwatch.com
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates - sharewise.com
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders - The Joplin Globe
Y-mAbs (YMAB) Q2 Revenue Falls 14% - The Motley Fool
Y-mAbs Therapeutics, Inc. SEC 10-Q Report - TradingView
Y-mAbs Therapeutics, Inc. Q2 2025 Financial Results - TradingView
Y-mAbs Q2 rev. $19.5mln, exceeds guidance, acquires Y-mAbs for $412mln. - AInvest
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Acquisition: SERB Pays 105% Premium in $412M Deal While Q2 Revenue Exceeds Guidance - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, YMAB, HLVX on Behalf of Shareholders - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) - PR Newswire
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast - 富途牛牛
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc.YMAB - Business Wire
Y-mAbs Q2 2025 Earnings Tomorrow: Key Updates Coming Amid SERB Pharma Transaction - Stock Titan
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains? - MSN
Mayer Brown advises the group Serb Pharmaceuticals on the structuring of the take-private of Y-mAb Therapeutics Inc. - Mayer Brown
BSR REIT ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS - The Globe and Mail
YmAbs Therapeutics' 103.3% Surge: A Sustainable Bull Case or a Volatile Flash in the Pan? - AInvest
Y-mAbs Therapeutics Stock Surges 103.3% on Acquisition Deal with SERB Pharmaceuticals - AInvest
Y-mAbs Therapeutics: A Biotech M&A Deal that Highlights the Value and Challenges of the Industry - AInvest
Y-mAbs Therapeutics: The Next Deal Showcases The Value And Challenges Of Biotech M&A - Seeking Alpha
Oppenheimer Downgrades Y-mAbs Therapeutics to Market Perform From Outperform, Adjusts Price Target to $3 From $4 - MarketScreener
Canaccord Genuity Downgrades Y-mAbs Therapeutics to Hold From Buy, Adjusts Price Target to $8.60 From $26 - MarketScreener
SERB Pharma to acquire Y-mAbs Therapeutics for $412m - World Pharmaceutical Frontiers
Wedbush Downgrades Y-mAbs Therapeutics to Neutral From Outperform, Cuts Price Target to $8.60 From $18 - MarketScreener
Y-mAbs Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
SERB bets on rare cancer drug in $412 million deal for Y-mAbs - The Pharma Letter
YmAbs Therapeutics (YMAB) Upgraded to Buy: Here's What You Should Know - MSN
Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S. - Mugglehead Magazine
Y-mAbs Therapeutics downgraded to Hold from Buy at Canaccord - TipRanks
Y-mAbs Therapeutics stock downgraded to Hold by Truist after SERB acquisition - Investing.com Canada
Y-mAbs Therapeutics downgraded to Hold from Buy at Brookline - TipRanks
Hold Rating Issued Amidst SERB Pharmaceuticals’ Acquisition of Y-mAbs Therapeutics - TipRanks
Y-mAbs strategic review culminates in buyout by SERB Pharma - FirstWord Pharma
Specialty pharma SERB to buy Y-mAbs in $412M all-cash deal - Endpoints News
Top Midday Gainers - MarketScreener
Y-mAbs Therapeutics downgraded to Hold from Buy at Clear Street - TipRanks
Nasdaq Down 50 Points; ISM Services PMI Declines In JulyAmeresco (NYSE:AMRC), Agilon Health (NYSE:AGL) - Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - GlobeNewswire Inc.
SERB to acquire Y-mAbs Therapeutics for $8.60 per share in cash - TipRanks
JonesTrading Downgrades Y-mAbs Therapeutics to Hold From Buy - MarketScreener
Y-mAbs-SERB Buyout: A Case Study in Biotech M&A Fairness and Board Accountability - AInvest
The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders - 富途牛牛
Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition By Investing.com - Investing.com South Africa
Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition - Investing.com
Y-mAbs Therapeutics Skyrockets 103%—What’s Fueling This Biotech’s Volatility? - AInvest
Corporate M&A and Shareholder Value: Assessing the Fairness of Y-mAbs' Sale to SERB Pharmaceuticals - AInvest
Sudden Rise for YMAB: Is It Sustainable? - StocksToTrade
Y-Mabs Therapeutics Announces Merger with SERB Pharmaceuticals - TipRanks
3.70%
1.02%
자본화:
|
볼륨(24시간):